Welcome to BioSeeker Group!

Large Pharma:2004 a year of Progress

Additional Information

Published Date Jan 18, 2005
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 174
PDF Fact Sheet View Fact Sheet for the report Large Pharma:2004 a year of Progress in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$1,950.00

Quick Overview

BioSeeker Group analyzes the progress made by the large pharmaceutical companies top oncology drug candidates whom has reached Phase III clinical evaluation.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Large Pharma:2004 a year of Progress.

    To find out more about Large Pharma:2004 a year of Progress, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Large Pharma:2004 a year of Progress is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

The gross majority of all drugs, which reach late stage of development, are someway or another passed on to the large pharmaceutical companies because they hold the capital needed to conduct the expensive clinical trials as well as the regulatory commitment needed to gain an approval. In this issue of our Cancer Highlight", BioSeeker Group analyzes the progress made by the large pharmaceutical companies top oncology drug candidates whom has reached Phase III clinical evaluation. This report provides you with update information on the most recent advances made and the competitive struggle that exists between the large pharmaceutical companies. The information structure in our cancer highlight reports will as well include a general description on drugs and targets and provide an easy reading format to track B2B collaborations and industry academic relationships.

Hallmarks of 2004 includes that BAY 43-9006 and CCI-779 were granted Fast Track Designition for treating patients with renal cell carcinoma. Fast Track Designition were also awarded to Xcytrin for treating patients brain metastases. In turn, Orphan Drug Status was granted to BAY 43-9006 for renal cancer, PI-88 for melanoma and Revlimid for myelodysplastic syndromes. Four FDA approvals were also reported during 2004. Avastin as well as Erbitux were both approved as treatment for colorectal cancer whereas Alimta was approved as treatment for mesothelioma. And very recently, Tarceva was approved as monotherapy to treat non-small cell lung cancer.

The year 2004 has been a year of competitive challenge for AstraZenacas drug Iresssa and Genetechs drug Tarceva. Both drugs target the human epidermal growth factor receptor 1 and have in near term gained FDA approval as treatments of NSCLC. Iressa in May 2003 and Tarceva in November 2004. Moreover, the marketed drug Iressa already on the market has been added to American Society of Clinical Oncology Clinical Practice guidelines. The fact that Tarceva demonstrate an improved survival benefit in advanced NSCLC patients the competitive situation is presently swinging away from Iressa and in favor for Tarceva.

Several drugs that are in Phase III are evaluated for treatment of breast cancer. Even though most candidates have been on the market for some years we do see substantial progress in this field. This indicates that a competitive situation is imminent between Pfizer and AstraZeneca. Two of the drugs, Aromasin and Faslodex both block the effects of the estrogen hormone. Pfizers drug Aromasin has been reported to improve disease-free survival and to be superior to Tamoxifen as a first line hormonal treatment for metastatic breast cancer. A potential threat for Aromasin is AstraZenecas drug Faslodex, which has been shown to be at least as effective as anastrozole and associated with a longer median duration of response.

As regard the treatment of colorectal cancer, several drugs are candidates to change the standard therapy. Xeloda is suggested as a replacement of 5-FU/LV in the adjuvant therapy of colon cancer. Edotecarin has been shown to be more potent than SN-38. Preliminary resultsfurther suggest that the combination of PTK787 with FOLFIRI as an option in patients with metastatic colorectal cancer. However, Genentechs drug Avastin is still held in high regard as the drug with the largest single sales potential. Even though FDA issued a warning that Avastin could increase the risk of stroke the prognosis is that Avastin is going to be combined with a wide range of 5FU-based chemotherapies. Based on recent positive interim result, Genentech further plans filing of a sBLA.

Drugs that will be of future interest are the niche of overcoming Gleevec resistance. Several research reports have been published in this field during the most recent years and we might expect this field to become a highly competitive area. A drug that in near term has been suggested to overcome Gleevec resistance is Pfizers SU11248. Data implicate that SU11248 can overcome Gleevec resistance in patients with metastatic GIST. Moreover, the addition of SU11248 to AML chemotherapy regimens could result in improved treatment results.

Beside above candidates developed by the large pharmaceutical companies, Celgenes thalidomide analogs are under intense investigations as a new agent with antimyeloma activity. During 2004 Celgene received FDA approvable letter for Thalomid sNDA in multiple myeloma. The anticipation of an accelerated approval is the results of a study comparing Thalomid plus dexamethasone to dexamethasone alone in previously untreated multiple myeloma patients.

Therapeutic candidates included in this analysis: Alimta, Aromasin, Avastin, Bay 43-9006, BMS-247550, CCI-779, Edotecarin, Erbitux, Faslodex, Gleevec, Herceptin, IMC-BEC2, Iressa, Lapatinib, MelVax, PTK787, Sarasar, SU011248, Tarceva, Thalomid (+thalidomide analogs) Tirapazamine and Xeloda.

Introduction
- Approval and New Development of Erbitux
- Two Drugs at War; Iressa versus Tarceva
- Breast Cancer Competition
- European Approval for Estrogen Receptor Downregulator
- Dual Kinase Inhibitor with Improved Effect in Breast Cancer
- Side effects & resistance
- Epothilone B analogues in Patients with Breast/Prostate Cancer
- Avastin safety warning unlikely limit use
- FDA backs drug for lung cancer treatment
- Late Stage Cancer Vaccine Back To The Bench
- Discontinued Phase III Studies: NSCLC
- New Therapeutic Option for Patients with Renal Cell Carcinoma
- Fast Track Status in Advanced Renal Cell Carcinoma
- Option For The Treatment of Colorectal Cancer
- New Drug to Replace Standard Chemotherapy in Colon Cancer?
- A Drug More Potent than Camptothecin
- Additional Revenues for Gleevec
- Overcoming Gleevec resistance
- Reactivating DNA-damaging in hypoxic tumors
- New agent with antimyeloma activity

Appendix

Table 1. Regulatory Agency Achievements 2004
Table 2. ALIMTA Near Term Progress
Table 3. Aromasin Near Term Progress
Table 4. Faslodex Near Term Progress
Table 5. Avastin Near Term Progress
Table 6. Bay 43-9006 Near Term Progress
Table 7. BMS-247550 Near Term Progress
Table 8. CCI-779 Near Term Progress
Table 9. Edotecarin Near Term Progress
Table 10. Erbitux Near Term Progress
Table 11. Gleevec Near Term Progress
Table 12. Lapatinib Near Term Progress
Table 13. Herceptin Near Term Progress
Table 14. IMC-BEC2 Near Term Progress
Table 15. Iressa Near Term Progress
Table 16. MelVax Near Term Progress
Table 17. PTK787 Near Term Progress
Table 18. Lonafarnib Near Term Progress
Table 19. SU011248 Near Term Progress
Table 20. Xeloda Near Term Progress
Table 21. Thalomid and thalidomide analogs Near Term Progress
Table 22. Tarceva Near Term Progress
Table 23. Tirapazamine Near Term Progress
Table 24. Xeloda Near Term Progress

Therapeutic candidates included in this analysis:
Alimta
Aromasin
Avastin
Bay 43-9006
BMS-247550
CCI-779
Edotecarin
Erbitux
Faslodex
Gleevec
Herceptin
IMC-BEC2
Iressa
Lapatinib
MelVax
PTK787
Sarasar
SU011248
Tarceva
Thalomid (+thalidomide analogs) Tirapazamine and Xeloda.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Large Pharma:2004 a year of Progress.
    To find out more about Large Pharma:2004 a year of Progress, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Large Pharma:2004 a year of Progress is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
This report will excel your competitive awareness and decrease your decision making time in managing apoptotic drug development in cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you. Learn More


Cancer Antibodies: Competitive Positioning for Success
This report is written for you to identify your competition and understand which targeting strategies are at work within antibody drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you. Learn More

Other selected research from the 'R&D' category:


Lung Cancer Drug Pipeline Update
BioSeeker Group have identified 552 companies plus partners who are today developing 809 lung cancer drugs in 884 developmental projects in cancer across 431 different targets. In addition, there are 10 suspended drugs and another 267 drugs where development has been ceased. Learn More


Interfering With Cytokine-Cytokine Receptor Interaction for the Treatment of Cancer Drug Pipeline Update
BioSeeker Group have identified 529 companies plus partners who are today developing 854 cytokine-cytokine receptor interaction interference drugs in 2473 developmental projects in cancer across 310 different targets. In addition, there are 10 suspended drugs and another 303 drugs where development has been ceased. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Colorectal Cancer, Melanoma and Antibodies
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Melanoma and by the compound strategy of Antibodies. Learn More


Prostate Cancer - A Therapeutic & Competitive Insight
In this report BioSeeker does not only describe and analyze the latest years of progress but as well provide an insight and framework to understand the complex field of prostate cancer therapeutics. Learn More